Drug Profile
Berzosertib - Merck KGaA
Alternative Names: Captisol® enabled VX 970; M-6620; MSC 2527093A; VX-970Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer EMD Serono Research & Development Institute; Massachusetts General Hospital; Merck KGaA; National Cancer Institute (USA); University of Oxford
- Class Amines; Antineoplastics; Isoxazoles; Pyrazines; Radiation-sensitising agents; Small molecules
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fallopian tube cancer; Gastric cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
- No development reported Acute myeloid leukaemia; Head and neck cancer; Oesophageal cancer
Most Recent Events
- 25 Jan 2024 Efficacy and adverse event data from a phase II trial in Urgenital cancer presented at the Genitourinary Cancers Symposium (ASCO-GeCS-2024)
- 11 Oct 2023 Efficacy and adverse events data from a phase II trial in Small cell lung cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 21 Jul 2023 EMD Serono Research & Development Institute completes phase-II DDRiver SCLC 250 trial in Small cell lung cancer (Combination therapy, Second-line therapy or greater) in Spain, Japan, Italy, France, China, Belgium and USA (IV) (NCT04768296)